Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GTQOC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PSMA-ADC
|
|||||
| Synonyms |
PSMA ADC (Progenics Pharmaceuticals)
Click to Show/Hide
|
|||||
| Organization |
PSMA Development Co. LLC; Lantheus Holdings, Inc.; Brown University; Progenics Pharmaceuticals, Inc.; The University of Texas At Dallas; Rhode Island Hospital
|
|||||
| Drug Status |
Terminated in phase 2
|
|||||
| Indication |
In total 2 Indication(s)
Glioblastoma [ICD11:2A00]
Terminated in phase 2
Prostate cancer [ICD11:2C82]
Terminated in phase 2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Fully human IgG1 Anti-PSMA mAb
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.